Mindfront Health won the 2023 Golden Bull Award for Its First Interactive Mental Health x Art Exhibition

This summer, Mindfront Health held "Two-way Life - Touching the Indifference and Warmth of the City", a first-of-its-kind virtual interactive mental health art exhibition and achieved immersive and in-depth dissemination. Recently, the exhibition stood out among more than 500 participating cases and won the "Best Industry Marketing Award" at the 2023 Digital Marketing Conference and Golden Bull Awards.

 

The event was hosted by the Chenghua District People's Government and the Digital Industry Innovation Research Center of Chengdu and was hosted by "PR People" and "Tips Experts". The award ceremony was held grandly in Shanghai on 7th December.

 

Luye Diagnostics Completed Over CNY 100 Million Yuan in Pre-A Round Financing

Luye Diagnostics announced that it has recently completed over CNY 100 million in pre-A round financing, led by Shangxian Lake Digital Economy Fund and Guolian Tongbao Capital, with additional investment from Luye Investment Group. This round of financing will continue to promote Luye Diagnostics’ research and development on leading underlying nucleic acid detection technologies, accelerate the construction of molecular diagnostic reagent production lines and the development of innovative products that meet clinical diagnostic needs.

Molecular diagnosis can analyze an individual's genome and provide personalized diagnosis. Its accuracy and information density are far superior to other diagnostic methods, and it helps achieve precise diagnosis, treatment, and prevention. Therefore, it is known as “the golden key to the precise medicine industry.” Data shows that the upstream raw material market share of the molecular diagnostic industry is mainly occupied by foreign brands, while the production of instruments and reagents in the midstream has been partially domesticated. With the continuous advancement in China’s medical technology and the continuous improvement of the medical and health service system, the demand for molecular diagnosis has greatly increased, and local enterprises continue to innovate independently and have gradually replaced or surpassed their foreign counterparts, bringing new technological changes to China's molecular diagnostics industry.

Liu Aona, Chairperson of Luye Diagnostics Group, pointed out: “The molecular diagnostic industry track, which Luye Diagnostics focuses on, is not only the foundation for the development of contemporary precision medicine, but also the fastest growing and most potential segment in the field of in vitro diagnostics. With its professional team and international presence, Luye Diagnostics has completed the construction of a complete molecular diagnostic operation system from zero to one, creating an integrated ecosystem from R&D to production to commercial operations. We hope to use this investment as an opportunity to continue to focus on the research and development and application of molecular diagnostic technology, continue to promote the registration and approval of several existing and new clinical products, and expand our business team and market. In the future, we aim to benefit society with more high-quality products in more mature business channels.”

Ella Jiang, CEO of Luye Diagnostics Group, said:“ We are honored to receive the recognition and support from investors. This financing will provide an important financial guarantee for Luye Diagnostics’ R&D and commercial expansion and will also accelerate our development process. As a life sciences company with multiple core patented technologies in genomics and molecular diagnostics, Luye Diagnostics Group looks forward to serving the urgent diagnostic and treatment needs of patients around the world and contributing to human health with high-quality domestic molecular diagnostic products and solutions.”

 

Luye Diagnostics Paves an Innovative Development Pathway for Precision Medicine Industry through Ecological Integration

The Wuxi Precision Medicine Ecosystem Conference and the Awards Ceremony for Luye Rising Stars Project, a collaborative effort by Luye Life Sciences Group, the National Medical Device Industry Technology Innovation Alliance, and the Management Committee of Wuxi Economic Development District, concluded successfully in Wuxi on 30th November.

Key figures from the medical device industry, including renowned experts, professors, and innovators, gathered to delved into the translation pathways for the cutting-edge of precision medicine technologies and envisioned a prosperous future for the industry. The event aims to catalyze the incubation and translation of innovative discoveries and propel the development of precision medical devices and the broader precision medicine clusters to unprecedented heights.

The event comprised two segments: a competition and a conference. On 29th November, the From Academia to Industry Special Session (Wuxi) of the 6th (2023) China Medical Devices Design & Entrepreneurship Competition, and the awards ceremony for Luye Rising Stars Project were held together. Nearly a hundred experts, scholars, industry leaders, and investors from the medical device field convened to discuss collaboration and plan for future development, contributing their expertise to the advancement of the precision medicine industry in the Wuxi Economic Development District.

Luye “Morning Star” Project, launched in the spring of this year, is dedicated to uniting diverse entities such as industrial parks, enterprises, research institutions, universities, and think tanks to promote the bench-to-bedside translation of innovative findings. Since its inception, the Project has received 70 applications from across the country, spanning various subfields of precision medicine.

‘Ploughing in the spring, weeding in the summer, harvesting in the autumn, and storing in the winter’. After two rounds of competition, winning projects are elected, including 1 Morning Star, 1 Extraordinary Star, and 2 Excellent Stars. With the support of the organizers and awards of CNY ¥200,000, ¥100,000 and ¥50,000 for the winning projects respectively, to help the excellent projects transformed into products, driving the development of the industry, and benefiting human health. 
 
Liu Aona, Chairperson of Luye Diagnostics Group, remarked, "Through this conference, we aim to collaboratively build a cross-sector and interdisciplinary ecosystem around precision medicine. We believe it will achieve a '1+1 greater than 2' synergy by fostering clusters that integrate industry, academia, and research.

 

“Every time I visit Wuxi this year, it never fails to surprise and fills my heart with high hopes for its future. In that sense, the city is truly living up to the connotation of its name – boundless scenery inspires confidence for the future. As the ‘Innovation Core’ of Wuxi's ‘One City with Dual Cores’ strategy, the Economic Development District has positioned itself as a pioneer in science and technology innovation and aggregated global resources for that purpose. At the same time, it has been driving the development of precision medicine through innovation, contributing to the safeguarding of people’s health. Luye Diagnostics and Luye Life Sciences Group, adhering to their philosophy of "Passionate for Life," respect and support the vibrant innovative spirit in the field of life sciences.

“Naturally, Luye Diagnostics and Wuxi Economic Development District found each other the perfect partner for the national headquarters project of Luye Diagnostics and the Luye Precision Medicine Cluster project. Together, we initiated the Project of Rising Stars in Precision Medicine. It aims to be a catalyst for translating the dazzling sparks of innovation in precision medicine into practice. We look forward to joining hands with other stakeholders in providing those exceptional teams with the right resources and environment so as to accelerate their endeavor for the benefit of humanity."

A number of KOLs gathered to start a roundtable dialogue with the theme of "ecological cooperation for mutual benefits".

Ms. Ella Jiang, CEO of Luye Diagnostics Group, said: “industrial innovation is fundamentally the in-depth combination of technological innovation and market demand. Luye Diagnostics has many technological innovations and has cooperated with a number of domestic universities and research institutes in scientific research and projects based on material science and diagnostic technology, and also introduced some international cutting-edge technologies through overseas mergers and acquisitions, conducted localization, and controlled the costs and carried out technological innovations. We hope to promote such innovative products and technology platforms to the international market, and look forward to leading more domestic diagnostic enterprises and technologies to go globally.

 

“Precision medical device is a strategic emerging industry which is multidisciplinary, knowledge-intensive, and high value-added. Currently in China, there is a need for cross-disciplinary talents, both in the industrial circle and in the whole education system. It is necessary for all parties to work together to strengthen the interaction, accelerate the industry's innovative development and transformation of scientific and technological achievements, enhance the competitiveness of products and enterprises strategic initiatives, thus forming a sustainable industry-university-research transformation and collaborative innovation in the field of precision medical devices, and realizing the vision of " ecological cooperation for mutual benefits ".

The forum was successfully concluded in a lively atmosphere. Through this conference, Luye Life Science Group and Luye Diagnostics continuously integrating the resources of industry, academia, research, medicine and management in precision medicine, strengthen the synergy with government, industry, academic circle and research institutes, creating new momentum to China’s precision medicine industry, realizing the vision of " ecological cooperation for mutual benefits ", opening the way to the innovative development of precision medicine industry.